Generic Competition And Pricing Pressures Hold Back AstraZeneca In The First Quarter
This article was originally published in The Pink Sheet Daily
AstraZeneca reports declines in revenues and operating profits in the 2011 first quarter, but expects its earnings per share will be boosted this year from tax and patent settlements.
You may also be interested in...
TOKYO - Shionogi & Co. Ltd. is fighting a two-front battle, recovery from the March 2011 earthquake and tsunami in Northern Japan and restructuring of its U.S. acquisition. The company formulated a mid-term plan to address ways to buffer the September 2016 patent loss of Crestor (rosuvastatin), by far the company's most important drug, but setbacks in the U.S. raise doubts about the company's ability to counter the patent cliff
Although GlaxoSmithKline's global sales declined by 10% and EPS rose by 9% during the first quarter, the UK Big Pharma sees signs of increased R&D productivity.
A California federal court rules that a PDL patent claim is invalid and that MedImmune did not have to pay royalties on sales by its ex-U.S. distributor Abbott; MedImmune may seek repayment of $280 million in royalties.